Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has announced its intention to sell all holdings in Teva Takeda Pharma Limited and its wholly owned subsidiary Teva Takeda Yakuhin Ltd. to JKI, a company established by a fund managed and operated by J-Will. This strategic move aligns with Teva’s Pivot to Growth strategy, enabling the company to concentrate on its innovative medicines business in Japan and explore new strategic directions within the country.
Focus on Innovative Medicines in Japan
The divestment is part of Teva’s broader efforts to streamline its operations and prioritize its innovative medicines business in Japan. By divesting from Teva Takeda Pharma Limited and Teva Takeda Yakuhin Ltd., Teva aims to sharpen its focus on areas with higher growth potential and better align with its long-term strategic goals.
Employee Transition and Deal Closure
The deal is expected to close by April 2025, and all employees of the business venture in Japan will remain employed, ensuring a smooth transition for the workforce. This acquisition by JKI highlights the ongoing interest in the pharmaceutical sector and the value of Teva’s operations in Japan.-Fineline Info & Tech
